{
    "nctId": "NCT06245889",
    "briefTitle": "PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC",
    "officialTitle": "A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "SULmax in relation to pCR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Stage II-III TNBC - estrogen receptor (ER) and progesterone receptor (PR) up to and including 10% is eligible\n2. Age \u2265 18 years\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n4. Eligible for standard chemo-immunotherapy as determined by treating physician, including consideration of:\n\n   1. Adequate marrow and organ function\n   2. Co-morbid conditions do not preclude the use of chemo-immunotherapy (such as uncontrolled autoimmune disease, or the use of immunosuppressive medications)\n5. Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study\n\nExclusion Criteria:\n\n1. Patients unable to undergo PET or MRI\n2. Evidence of metastatic disease or loco-regional recurrence (i.e. distant or chest wall recurrence)\n3. Inflammatory breast cancer\n4. Previous treatment with paclitaxel, carboplatin, or immune checkpoint inhibitors",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}